NCT07109778

Copper to Zinc Ratio in End Stage Renal Disease Patients Outcome

Impact of Copper to Zinc Ratio on Outcome of End Stage Renal Disease Patients

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 150 (estimated)
• Sponsor: Minia University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The goal of this observational clinical trial is to Study the impact of copper to zinc ratio on the outcome of ESRD patients

Detailed description

End-stage renal disease (ESRD) carries high morbidity and mortality due to cardiovascular complications, highlighting the need for ongoing research. Trace elements as copper (Cu), and zinc (Zn), are essential for physiological functions, enzyme activity, metabolism, and immune defense. In ESRD patients, Cu and Zn imbalances, with a higher Cu/Zn ratio are linked to greater cardiovascular problems. The relationship between the Cu/Zn ratio and clinical outcomes in ESRD needs more exploration

Conditions

• ESRD (End Stage Renal Disease)
• Control Condition

Timeline

• Start date: 2025-08-01
• Primary completion: 2026-02-01
• Completion: 2026-04-01
• First posted: 2025-08-07
• Last updated: 2025-08-07

Locations

1 site across 1 country: Egypt